There are 2137 resources available
1052P - Genetic modification of Iovance’s TIL through TALEN-mediated knockout of PD-1 as a strategy to empower TIL therapy for cancer
Presenter: Krit Ritthipichai
Session: E-Poster Display
Resources:
Abstract
1053P - Iovance generation-2 tumour-infiltrating lymphocyte (TIL) product is reinvigorated during the manufacturing process
Presenter: Michelle Simpson-Abelson
Session: E-Poster Display
Resources:
Abstract
1054P - Treatment history affects bone marrow toxicity after conditioning non-myeloablative chemotherapy in adoptive cell therapy in non-melanoma cancer patients
Presenter: Anders Kverneland
Session: E-Poster Display
Resources:
Abstract
1055P - Updated results of subcutaneous (SC) anti-programmed cell death 1 (PD-1) receptor antibody PF-06801591 for locally advanced or metastatic non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC)
Presenter: Byong Chul Cho
Session: E-Poster Display
Resources:
Abstract
1056P - Durvalumab (D) in combination with chemoradiotherapy (CRT) in solid tumours: Phase I CLOVER study
Presenter: Julie Bauman
Session: E-Poster Display
Resources:
Abstract
1057P - Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing
Presenter: Benjamin Markman
Session: E-Poster Display
Resources:
Abstract
1058P - A single-centre, prospective, open-label, single-arm trial of toripalimab with nab-paclitaxel and S-1 as a neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC)
Presenter: Guoqing Zhang
Session: E-Poster Display
Resources:
Abstract
1059P - NEMIO: A randomized phase I-II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
Presenter: Constance Thibault
Session: E-Poster Display
Resources:
Abstract
1060P - HER2-XPAT, a novel protease-activatable pro-drug T-cell engager (TCE), engineered to address on-target, off tumour toxicity and provide large predicted safety margins in non-human primate (NHP)
Presenter: Fiore Cattaruzza
Session: E-Poster Display
Resources:
Abstract
1061P - TCR and HLA analysis of patients in a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)
Presenter: David Anderson
Session: E-Poster Display
Resources:
Abstract